Latest Breaking News On - Refractory multiple - Page 2 : vimarsana.com

TECVAYLI® (teclistamab-cqyv) biweekly dosing approved by the U S FDA for the treatment of patients with relapsed or refractory multiple myeloma

/PRNewswire/ Johnson & Johnson announced today that the U.S. Food and Drug Administration (FDA) has approved the supplemental Biologics License Application.

United statesChristie corbettRachel kobosPrnewswire johnsonSatu glaweNational cancer instituteEuropean commissionAmerican society of clinical oncologyExchange commissionAmerican cancer societyOncology research developmentOther administration reactionsSurveillance research programJohnson incJanssen biotech incNone of janssen research development

Data From 2023 ASH Annual Meeting Provide Positive Updates in Multiple Myeloma

Experts discuss treatment in newly diagnosed multiple myeloma and the role of CAR T-cell therapies and bispecifics in relapsed/refractory disease.

United statesSan diegoCaitlin costelloKrinak patelAmerican society of clinical oncology annual meetingOnclive peer exchangeAmerican society of hematology annual meeting expositionAmerican societyHematology annual meetingNewly diagnosed multipleCell therapyRefractory multipleClinical oncology annual meetingCart cell therapiesBispecifics in relapsed refractory diseaseNewly diagnosed multiple myeloma

Ichnos and Glenmark take a collaborative leap to accelerate innovation in Cancer Treatment with their alliance

This alliance brings together drug innovation capabilities of Ichnos and Glenmark to develop cutting-edge therapies for the treatment of hematological.

New yorkUnited statesGlenn saldanhaCyril kontoIchnos sciences incPrnewswire ichnos sciences incGlenmark pharmaceuticals ltdGlenmark pharmaceuticalsIchnos glenmark innovationNew york cityManaging directorGlenmark innovationAsset pipelineRefractory multipleAcute lymphoblastic leukemiaIchnos sciences inc

Ichnos and Glenmark take a collaborative leap to accelerate innovation in Cancer Treatment with their alliance

Ichnos and Glenmark take a collaborative leap to accelerate innovation in Cancer Treatment with their alliance
lelezard.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from lelezard.com Daily Mail and Mail on Sunday newspapers.

New yorkUnited statesCyril kontoGlenn saldanhaIchnos sciences incGlenmark pharmaceuticals ltdPrnewswire ichnos sciences incCancer treatmentIchnos glenmarkGlenmark pharmaceuticalsIchnos glenmark innovationNew york cityManaging directorGlenmark innovationAsset pipelineRefractory multiple

Oricell Announces FDA Clearance of IND Application for OriCAR-017, a novel GPRC5D Targeted CAR-T Cell Therapy Utilizing the Company s Proprietary Platform, for the Treatment of Relapsed/Refractory Multiple Myeloma

Oricell Announces FDA Clearance of IND Application for OriCAR-017, a novel GPRC5D Targeted CAR-T Cell Therapy Utilizing the Company s Proprietary Platform, for the Treatment of Relapsed/Refractory Multiple Myeloma
lelezard.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from lelezard.com Daily Mail and Mail on Sunday newspapers.

Helen yangDrug administrationProprietary platformRefractory multipleInvestigational new drugInvestigator initiated trialChief scientific officerChief executive officerOricell therapeutics holdings limited